AJ Lanigan: Certainly. The Truth is, pharma firms are earning major money with therapies like Keytruda and Opdivo that deal with PD-1 and PD-L1. Here’s the super awesome section: imagine checkpoints as targeted traffic signals. You don’t want an immune technique that’s working wild similar to a freight prepare over waiting for link from Social Bookmarking (3)